160800-57-7|澳瑞他汀E|Auristatin E|MFCD25976744-范德生物科技公司

澳瑞他汀E

NMR下载 COA and HPLC MSDS下载
names：
Auristatin E
CAS号：
160800-57-7
MDL Number： MFCD25976744
MF(分子式)： C40H69N5O7 MW(分子量)： 732.01
EINECS:No data available Reaxys Number:No data available
Pubchem ID:11498622 Brand:BIOFOUNT

澳瑞他汀E(160800-57-7,Auristatin E)是dolastatin 10的合成类似物。澳瑞他汀E是高效的抗有丝分裂剂。澳瑞他汀E抑制微管蛋白聚合。澳瑞他汀E是一种具有细胞毒性的微管蛋白修饰剂，澳瑞他汀E具有有效的选择性抗肿瘤活性。

货品编码	规格	纯度	价格 (¥)	现价(¥)	特价(¥)	库存描述	数量	总计 (¥)
YZM000916-5mg	5mg	99.3%	¥ 7593.00	¥ 7593.00		2-3天	- +	¥ 0.00
YZM000916-1mg	1mg	99.3%	¥ 3412.00	¥ 3412.00		2-3天	- +	¥ 0.00

大包装询价提供各种包装，敬请垂询
收藏商品商品点评加入购物车立即购买

快速询价

收起

你想询价的产品

*产品名称：

CAS号：

产品编号：

需求描述：

请准确填写您的联系方式，以便为您提供最好的服务。

*公司名称：

*电子邮箱：

联系人：

*电话：

*验证码：

询价

中文别名	澳瑞他汀E(160800-57-7,Auristatin E),澳瑞他汀E抑制剂
英文别名	Auristatin E(160800-57-7)
CAS号	160800-57-7
SMILES	CC(C)[C@H](N(C)C)C(N[C@H](C(N([C@@H]([C@@H](C)CC)[C@@H](CC(N1CCC[C@@]1([H])[C@H](OC)[C@@H](C)C(N[C@H](C)[C@H](C2=CC=CC=C2)O)=O)=O)OC)C)=O)C(C)C)=O
Inchi	InChI=1S/C40H69N5O7/c1-14-26(6)35(44(11)40(50)33(24(2)3)42-39(49)34(25(4)5)43(9)10)31(51-12)23-32(46)45-22-18-21-30(45)37(52-13)27(7)38(48)41-28(8)36(47)29-19-16-15-17-20-29/h15-17,19-20,24-28,30-31,33-37,47H,14,18,21-23H2,1-13H3,(H,41,48)(H,42,49)/t26-,27+,28+,30-,31+,33-,34-,35-,36+,37+/m0/s1
InchiKey	WOWDZACBATWTAU-FEFUEGSOSA-N
分子式 Formula	C40H69N5O7
分子量 Molecular Weight	732.01
闪点 FP	480.6±34.3 °C
熔点 Melting point	92-94 °C
沸点 Boiling point	871.0±65.0 °C at 760 mmHg
Polarizability极化度	81.2±0.5 10-24cm3
密度 Density	1.1±0.1 g/cm3
蒸汽压 Vapor Pressure	0.0±0.3 mmHg at 25°C
溶解度Solubility
性状	浅黄色至黄色固体粉末
储藏条件 Storage conditions	在-20°C条件下保存3年,在4°C条件下保存2年

澳瑞他汀E(160800-57-7,Auristatin E)实验注意事项：
1.实验前需戴好防护眼镜，穿戴防护服和口罩，佩戴手套，避免与皮肤接触。
2.实验过程中如遇到有毒或者刺激性物质及有害物质产生，必要时实验操作需要手套箱内完成以免对实验人员造成伤害
3.实验后产生的废弃物需分类存储，并交于专业生物废气物处理公司处理，以免造成环境污染

Auristatin E(160800-57-7) Experimental considerations:
1. Wear protective glasses, protective clothing and masks, gloves, and avoid contact with the skin during the experiment.
2. The waste generated after the experiment needs to be stored separately, and handed over to a professional biological waste gas treatment company to avoid environmental pollution.

Tag:澳瑞他汀E(160800-57-7,Auristatin E),澳瑞他汀E试剂,澳瑞他汀E抑制剂,澳瑞他汀E修饰剂,澳瑞他汀E的作用,澳瑞他汀E的合成,澳瑞他汀E的纯度,澳瑞他汀E的质量,澳瑞他汀E的效果,澳瑞他汀E的使用,澳瑞他汀E的注意事项,澳瑞他汀E的生产

产品说明	澳瑞他汀E(160800-57-7,Auristatin E)是一种具有细胞毒性的微管蛋白修饰剂，澳瑞他汀E具有有效的选择性抗肿瘤活性。
Introduction	Auristatin E (160800-57-7,澳瑞他汀E) is a cytotoxic tubulin modifier. Auristatin E has effective and selective anti-tumor activity.
Application1
Application2
Application3

警示图
危险性	warning
危险性警示	Not available
安全声明	H303吞入可能有害+H313皮肤接触可能有害+H2413吸入可能对身体有害
安全防护	P264处理后彻底清洗+P280戴防护手套/穿防护服/戴防护眼罩/戴防护面具+P305如果进入眼睛+P351用水小心冲洗几分钟+P338取出隐形眼镜（如果有）并且易于操作,继续冲洗+P337如果眼睛刺激持续+P2393获得医疗建议/护理
备注	实验过程中防止吸入、食入，做好安全防护

A Novel Affibody-Auristatin E Conjugate With a Potent and Selective Activity Against HER2+ Cell Lines PMID 27227324; Journal of immunotherapy (Hagerstown, Md. : 1997) 2016 Jul; 39(6):223-32 Name match

A Conjugate Based on Anti-HER2 Diaffibody and Auristatin E Targets HER2-Positive Cancer Cells PMID 28216573; International journal of molecular sciences 2017 Feb; 18(2): Name matches: monomethyl auris

A phase I study of the antibody drug conjugate ASG-5ME, an SLC44A4-targeting antibody carrying auristatin E, in metastatic castration-resistant prostate cancer PMID 30725389; Investigational new drugs

Preclinical validation of anti-TMEFF2-auristatin E-conjugated antibodies in the treatment of prostate cancer

CR011, a fully human monoclonal antibody-auristatin E conjugate, for the treatment of melanoma

1.An anti-HER2 antibody conjugated with monomethyl auristatin E is highly effective in HER2-positive human gastric cancer.
Li H1, Yu C2, Jiang J3, Huang C2, Yao X1, Xu Q2, Yu F2, Lou L4, Fang J1,5,6. Cancer Biol Ther. 2016 Apr 2;17(4):346-54. doi: 10.1080/15384047.2016.1139248. Epub 2016 Feb 6.
Antibody-drug conjugate (ADC) is a novel class of therapeutics for cancer target therapy. This study assessed antitumor activity of ADC with an antimitotic agent, monomethyl auristatin E (MMAE) and a humanized monoclonal anti-HER2 antibody, hertuzumab, in gastric cancer. The efficacy of hertuzumab-MC-Val-Cit-PAB-MMAE (hertuzumab-vcMMAE) on human epidermal growth factor receptor 2 (HER2) positive human gastric cancer cells, NCI-N87, was evaluated in vitro and in vivo. The cytotoxicity of hertuzumab was significantly enhanced after conjugation with MMAE. Compared to trastuzumab, hertuzumab had a higher affinity to HER2 and had more potent antibody-dependent cell-mediated cytotoxicity (ADCC) activity in vitro. After conjugation with MMAE, the binding specificity for HER2 was not affected. Furthermore, the internalization of hertuzumab-vcMMAE in HER2 positive gastric cancer cells was verified. Although the conjugation of hertuzumab and MMAE decreased the ADCC effect, the overall cytotoxicity was dramatically increased in HER2 positive gastric cancer cells.

对不起，暂无产品评价！

MSDS

SDS 1.0 中文

展开

SDS 1.0 英文

展开